Insider trading

Period: 12 months Stock: JNJ Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

18 decisions over 12 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

18 decisions over 12 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

18 decisions over 12 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

18 decisions over 12 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
18 decisions over 12 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
18 decisions over 12 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

18 decisions over 12 months
Stock
Insider
Type ?
Why it stands out
2 Sep 2026
Schmid Timothy EVP, WW Chair, MedTech
Sold at will 2×
$9.23M 33,597 at 274.74
56.9%
Sold half or more
17 Aug 2026
Taubert Jennifer L EVP, WWC. Innovative Medicine
Sold at will
$3.95M 15,000 at 263.36
7.2%
Not planned
13 Aug 2026
Duato Joaquin CEO and Chairman of the Board
Sold at will 2×
$32.20M 123,291 at 261.17
30.9%
Not planned
6 Aug 2026
Forminard Elizabeth EVP, Chief Legal Officer
Sold at will 2×
$4.09M 15,918 at 257.00
48.4%
Not planned
5 Aug 2026
Duato Joaquin CEO and Chairman of the Board
Sold at will 2×
$12.52M 48,480 at 258.15
14.9%
Not planned
20 Jul 2026
Broadhurst Vanessa EVP, Global Corp Affairs
Sold at will
$5.79M 23,054 at 251.27
50.1%
Sold half or more
11 Jun 2026
Wengel Kathryn E EVP, Chief TO and Risk Officer
Sold at will
$2.41M 10,000 at 241.15
8.0%
Not planned
27 Feb 2026
Decker Robert J VP Corporate Controller
Sold at will
$1.01M 4,075 at 247.87
14.7%
Not planned
20 Feb 2026
Schmid Timothy EVP, WW Chair, MedTech
Sold at will
$324.76K 1,322 at 245.66
4.9%
Not planned
18 Feb 2026
Schmid Timothy EVP, WW Chair, MedTech
Sold at will 2×
$5.53M 22,623 at 244.33
45.8%
Not planned
17 Feb 2026
Wolk Joseph J Exec VP, CFO
Sold at will 4×
$21.77M 89,654 at 242.80
86.5%
Sold half or more
17 Feb 2026
REED JOHN C EVP, Innovative Medicine, R&D
Sold at will 3×
$13.11M 53,931 at 243.00
83.5%
Sold half or more
17 Feb 2026
Swanson James D. EVP, CIO
Sold at will
$4.98M 20,521 at 242.70
44.4%
Not planned
17 Feb 2026
Broadhurst Vanessa EVP, Global Corp Affairs
Sold at will
$1.51M 6,197 at 243.39
21.2%
Not planned
13 Feb 2026
Swanson James D. EVP, CIO
Sold at will 2×
$10.13M 41,559 at 243.73
62.4%
Sold half or more
26 Jan 2026
Duato Joaquin CEO and Chairman of the Board · indirect
Sold at will 2×
$22.12M 100,000 at 221.23
76.4%
Sold half or more
26 Nov 2025
MORIKIS JOHN G Director
Bought
$257.69K 1,250 at 206.15
209%
First buy on file
17 Oct 2025
REED JOHN C EVP, Innovative Medicine, R&D
Sold at will
$4.19M 21,721 at 192.71
67.1%
Sold half or more
Showing 1–18 of 18.